OUR STORY
Our Vision
Our vision is to be a leader in identifying, developing and commercializing novel drugs that address unmet needs of people with rare cancer conditions.
Learn more about us:
TOP STORIES
Ascelia Pharma achieves Last Patient Last Visit (LPLV) in the Orviglance Phase 3 SPARKLE Study which now includes 85 completed patients.
2023-03-03 10:07:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that the Last Patient Last Visit (LPLV) has […]
TOP STORIES
Ascelia Pharma meets major milestone with patient enrollment completion for Orviglance Phase 3 Study, SPARKLE
2023-02-24 07:30:00
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced the successful completion of the patient enrollment in [&h …
TOP STORIES
New Strong Orviglance Data Support Successful SPARKLE Completion with Substantially Fewer Patients
2022.12.06
Ascelia Pharma AB (publ) (ticker: ACE), a biotech focused on improving the life of people living with rare cancer conditions, today announced that new data show that the pivotal Phase […]
Upcoming Events
Latest News
Presentations & Articles
INVESTOR
Shortcut to our latest Financial Reports
Key downloads
QUARTERLY REPORT Q1 2023: Orviglance phase 3 study, SPARKLE, Last Patient Last Visit (LPLV) has been completedCorrection: Ascelia Pharma publishes annual report for 2022Ascelia Pharma publishes annual report for 2022QUARTERLY REPORT Q4 2022: Orviglance phase 3 study, SPARKLE, expected to be completed in Q1 2023.QUARTERLY REPORT Q3 2022: Successful completion of two out of three studies for regulatory submission